465 related articles for article (PubMed ID: 19238094)
41. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study.
Duvoux C; Zanditenas D; Hézode C; Chauvat A; Monin JL; Roudot-Thoraval F; Mallat A; Dhumeaux D
Hepatology; 2002 Aug; 36(2):374-80. PubMed ID: 12143045
[TBL] [Abstract][Full Text] [Related]
42. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation.
Alessandria C; Ozdogan O; Guevara M; Restuccia T; Jiménez W; Arroyo V; Rodés J; Ginès P
Hepatology; 2005 Jun; 41(6):1282-9. PubMed ID: 15834937
[TBL] [Abstract][Full Text] [Related]
43. Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study.
Appenrodt B; Wolf A; Grünhage F; Trebicka J; Schepke M; Rabe C; Lammert F; Sauerbruch T; Heller J
Liver Int; 2008 Aug; 28(7):1019-25. PubMed ID: 18410283
[TBL] [Abstract][Full Text] [Related]
44. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial.
Mitzner SR; Stange J; Klammt S; Risler T; Erley CM; Bader BD; Berger ED; Lauchart W; Peszynski P; Freytag J; Hickstein H; Loock J; Löhr JM; Liebe S; Emmrich J; Korten G; Schmidt R
Liver Transpl; 2000 May; 6(3):277-86. PubMed ID: 10827226
[TBL] [Abstract][Full Text] [Related]
45. Does hepatorenal syndrome affect the result of liver transplantation? Clinical observations.
Park I; Moon E; Hwang JA; Yu S; Kim BW; Wang HJ; Shin GT; Kim H
Transplant Proc; 2010 Sep; 42(7):2563-6. PubMed ID: 20832544
[TBL] [Abstract][Full Text] [Related]
46. Treatment of hepatorenal syndrome.
Kiser TH; Maclaren R; Fish DN
Pharmacotherapy; 2009 Oct; 29(10):1196-211. PubMed ID: 19792993
[TBL] [Abstract][Full Text] [Related]
47. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study.
Pomier-Layrargues G; Paquin SC; Hassoun Z; Lafortune M; Tran A
Hepatology; 2003 Jul; 38(1):238-43. PubMed ID: 12830007
[TBL] [Abstract][Full Text] [Related]
48. Hepatorenal syndrome: are we missing some prognostic factors?
Olivera-Martinez M; Sayles H; Vivekanandan R; D' Souza S; Florescu MC
Dig Dis Sci; 2012 Jan; 57(1):210-4. PubMed ID: 21850494
[TBL] [Abstract][Full Text] [Related]
49. Alcoholic cirrhosis-associated hepatorenal syndrome treated with vasoactive agents.
Esrailian E; Runyon BA
Nat Clin Pract Nephrol; 2006 Mar; 2(3):169-72. PubMed ID: 16932415
[TBL] [Abstract][Full Text] [Related]
50. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study.
Alessandria C; Ottobrelli A; Debernardi-Venon W; Todros L; Cerenzia MT; Martini S; Balzola F; Morgando A; Rizzetto M; Marzano A
J Hepatol; 2007 Oct; 47(4):499-505. PubMed ID: 17560680
[TBL] [Abstract][Full Text] [Related]
51. New treatments of hepatorenal syndrome.
Arroyo V; Terra C; Ginès P
Semin Liver Dis; 2006 Aug; 26(3):254-64. PubMed ID: 16850375
[TBL] [Abstract][Full Text] [Related]
52. Long-term treatment of hepatorenal syndrome as a bridge to liver transplantation.
Caraceni P; Santi L; Mirici F; Montanari G; Bevilacqua V; Pinna AD; Bernardi M
Dig Liver Dis; 2011 Mar; 43(3):242-5. PubMed ID: 20833118
[TBL] [Abstract][Full Text] [Related]
53. Clinical outcomes of patients with hepatorenal syndrome after living donor liver transplantation.
Lee JP; Kwon HY; Park JI; Yi NJ; Suh KS; Lee HW; Kim M; Oh YK; Lim CS; Kim YS
Liver Transpl; 2012 Oct; 18(10):1237-44. PubMed ID: 22714872
[TBL] [Abstract][Full Text] [Related]
54. Midodrine is effective and safe therapy for intradialytic hypotension over 8 months of follow-up.
Cruz DN; Mahnensmith RL; Brickel HM; Perazella MA
Clin Nephrol; 1998 Aug; 50(2):101-7. PubMed ID: 9725781
[TBL] [Abstract][Full Text] [Related]
55. Terlipressin is superior to midodrine/octreotide for hepatorenal syndrome type 1.
Kalambokis GN; Baltayiannis G; Christodoulou D; Christou L
Eur J Gastroenterol Hepatol; 2017 Dec; 29(12):1428-1429. PubMed ID: 29111999
[No Abstract] [Full Text] [Related]
56. Terlipressin vs Midodrine Plus Octreotide for Hepatorenal Syndrome-Acute Kidney Injury: A Propensity Score-Matched Comparison.
Gonzalez SA; Chirikov VV; Wang WJ; Huang X; Jamil K; Simonetto DA
Clin Transl Gastroenterol; 2023 Dec; 14(12):e00627. PubMed ID: 37622521
[TBL] [Abstract][Full Text] [Related]
57. Diagnosis and treatment of hepatorenal syndrome.
Ginès P
Baillieres Best Pract Res Clin Gastroenterol; 2000 Dec; 14(6):945-57. PubMed ID: 11139348
[TBL] [Abstract][Full Text] [Related]
58. Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation.
Wong F; Leung W; Al Beshir M; Marquez M; Renner EL
Liver Transpl; 2015 Mar; 21(3):300-7. PubMed ID: 25422261
[TBL] [Abstract][Full Text] [Related]
59. Diagnosis and treatment of acute renal failure in patients with cirrhosis.
Moreau R; Lebrec D
Best Pract Res Clin Gastroenterol; 2007; 21(1):111-23. PubMed ID: 17223500
[TBL] [Abstract][Full Text] [Related]
60. The Treatment of Hepatorenal Syndrome.
Cavallin M; Fasolato S; Marenco S; Piano S; Tonon M; Angeli P
Dig Dis; 2015; 33(4):548-54. PubMed ID: 26159272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
